Is preexisting antitumor CD4 T cell response indispensable for the chemotherapy induced immune regression of cancer? - Inserm - Institut national de la santé et de la recherche médicale Access content directly
Journal Articles OncoImmunology Year : 2012

Is preexisting antitumor CD4 T cell response indispensable for the chemotherapy induced immune regression of cancer?

Abstract

Insights into antitumor T-cell responses may help the development of more efficient treatments for lung cancer. The interplay between preexisting antitumor CD4(+) T-cell responses and platinum-based chemotherapy is crucial to improve patient survival. Accumulating evidence confirms that selecting cancer patients in whom chemotherapy can activate an anticancer immune response would largely improve the success of novel therapeutic approaches.
Fichier principal
Vignette du fichier
23_2012ONCOIMM0238.pdf (181.89 Ko) Télécharger le fichier
Origin : Publisher files allowed on an open archive
Loading...

Dates and versions

inserm-00826885 , version 1 (30-05-2013)

Identifiers

Cite

Yann Godet, Magalie Dosset, Christophe Borg, Olivier Adotevi. Is preexisting antitumor CD4 T cell response indispensable for the chemotherapy induced immune regression of cancer?. OncoImmunology, 2012, 1 (9), pp.1617-1619. ⟨10.4161/onci.21513⟩. ⟨inserm-00826885⟩

Collections

INSERM UNIV-FCOMTE
119 View
188 Download

Altmetric

Share

Gmail Facebook X LinkedIn More